Guangzhou Innogen Pharmaceutical Group Co., Ltd. (2591)

Guangzhou Innogen Pharmaceutical Group Co., Ltd. is a pharmaceutical manufacturing company specializing in the development, production, and distribution of medicinal products. Established in 2014 and headquartered in Guangzhou, China, the company focuses on medicines aimed at treating conditions such as diabetes, arthritis, gastric diseases, and infections, with products offering heat clearing and anti-toxic effects. Its pharmaceutical offerings serve key therapeutic areas relevant to chronic and acute illnesses, reflecting its role in supporting both preventative and remedial healthcare solutions. Operating as part of the broader biotechnology and pharmaceuticals sector, the company conducts business across the healthcare value chain, from research and development through to distribution. Guangzhou Innogen Pharmaceutical Group Co., Ltd. plays a significant role in enhancing access to essential medicines and addressing evolving healthcare demands in its market, though it does not currently distribute dividends to shareholders and remains focused on reinvesting within its business.